Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:ABUS

Arbutus Biopharma Q3 2026 Earnings Date & Estimates

Arbutus Biopharma logo
$4.22 0.00 (0.00%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$4.22 +0.00 (+0.12%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arbutus Biopharma is estimated to report Q3 2026 earnings on Monday, November 16, 2026. The conference call is scheduled for November 12, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arbutus Biopharma in Q3 2026

Arbutus Biopharma is expected to post earnings of -$0.0232 per share on revenue of $1.00 million. In the same quarter a year earlier Arbutus Biopharma reported -$0.04 per share on revenue of $0.53 million. Arbutus Biopharma last reported on August 13, 2026, posting -$0.03 per share and missing the -$0.02 consensus estimate. Arbutus Biopharma has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0232
Expected Revenue
$1.00 million
Prior-Year EPS
-$0.04
Prior-Year Revenue
$0.53 million
Expected Revenue Growth
+89.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.03 (Missed by -$0.01)
Last Quarter Revenue
$1.01 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Arbutus Biopharma Q3 2026 Earnings FAQ

Arbutus Biopharma (NASDAQ:ABUS) is estimated to report Q3 2026 earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Arbutus Biopharma's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arbutus Biopharma to post earnings of -$0.0232 per share for Q3 2026.

The consensus revenue estimate for Arbutus Biopharma is $1.00 million for Q3 2026.

Arbutus Biopharma Earnings Headlines

Arbutus Biopharma (NASDAQ:ABUS) & Syndax Pharmaceuticals (NASDAQ:SNDX) Head-To-Head Comparison
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114270
Contrasting Arbutus Biopharma (NASDAQ:ABUS) & Evaxion A/S (NASDAQ:EVAX)
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114056
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952856-arbutus-biopharma-230m-buyback-and-moderna-cash-de-risk-the-path-to-a-potential-hbv-cure
Arbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender Offer
October 2, 2026  |  marketscreener.comM
Tranche Update on Arbutus Biopharma Corporation's Equity Buyback Plan announced on August 21, 2026.
October 1, 2026  |  marketscreener.comM
See More Arbutus Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email.

About Arbutus Biopharma

Arbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection and other viral diseases. The company’s research programs are based primarily on RNA interference (RNAi) therapeutics and small-molecule compounds designed to suppress viral replication and address the underlying biology of persistent infection.

Arbutus’ HBV pipeline has included AB-729, an investigational subcutaneously administered RNAi therapeutic intended to reduce hepatitis B surface antigen, and AB-836, an investigational oral capsid inhibitor designed to interfere with HBV replication. The company also develops and licenses lipid nanoparticle delivery technology, which is intended to help transport nucleic acid medicines into cells.

The company traces its history to Tekmira Pharmaceuticals, which combined with OnCore Biopharma in 2015 and adopted the Arbutus Biopharma name. Arbutus is headquartered in Warminster, Pennsylvania, and conducts research and clinical development through collaborations and studies involving international markets. Its leadership and development strategy have centered on advancing targeted therapies for chronic viral infections while leveraging its expertise in RNA medicines and drug-delivery technologies.

View Arbutus Biopharma Profile
Earnings Tools